


LabCorp and Envigo Sign Innovative Agreement to Expand Covance's Nonclinical Drug Development Capabilities and Create an Independent Research Models and Services Provider



STRATEGIC FIT

- Simplifies and focuses Covance's nonclinical research business model
- Enhances Covance's nonclinical capabilities with additional scientific and technical expertise, including respiratory
- Adds facilities in Europe and the U.S. East Coast to meet growing client needs
- Combines two complementary premier suppliers of research models and services
- Enables clients to more easily source the best models to meet clients' research needs

Multi-year, renewable strategic supply agreement provides clients access to their current high-quality research models and services, as well as expanded access to full range of nonclinical offerings from both providers

COVANCE EARLY DEVELOPMENT

 **4,200 EMPLOYEES**
 **13 LOCATIONS IN 7 COUNTRIES**

ENVIGO

 **1,200 EMPLOYEES**
 **>20 LOCATIONS IN 8 COUNTRIES**


COMPLEMENTARY OFFERINGS AFTER TRANSACTION CLOSE

- General toxicology
- Genetic toxicology
- Safety pharmacology
- Immunology and immunotoxicology solutions
- Immunology services
- Developmental and reproductive toxicology
- Metabolism and PKPD modeling
- Specialty
 - Ocular
 - Respiratory
 - Infusion
- Pathology
- Pharma consultancy
- Pharmacology models
- Bioanalytical
- Chemistry, Manufacturing and Controls
- Archiving


- Rodents
- Canines
- Rabbits
- Non-human primates
- Contract breeding
- Biological products and services
- Research model support services
- Genetic testing
- Surgical services
- Diet, bedding and enrichment

RESEARCH-FOCUSED CLIENT BASE AFTER TRANSACTION CLOSE

Covance Early Development



Envigo



“This transaction creates a best-of-both-worlds situation for customers – two leading providers with expanded capabilities and reach, each with a dedicated core focus. As a result, we can create growth opportunities for our exceptional people.”

John Rattliff, CEO, Covance



“We have made a bold move for our customers and employees by creating a new industry offering. We are committed to providing the highest-quality research models to help build a healthier and safer world.”

Dr. Adrian Hardy, President and CEO, Envigo

